1,434 results match your criteria Current Oncology [Journal]


A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.

Curr Oncol 2019 Feb 1;26(1):e115-e118. Epub 2019 Feb 1.

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan.

Nivolumab, an anti-PD-1 antibody, is now considered an important therapeutic agent in several advanced malignancies. However, immune-related adverse events such as endocrinopathies have been reported with its use. Thyroid disorder and isolated adrenocorticotropic hormone deficiency have frequently been reported as nivolumab-induced immune-related adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380632PMC
February 2019
2 Reads

Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Curr Oncol 2019 Feb 1;26(1):e111-e114. Epub 2019 Feb 1.

First Department of Clinical Oncology, Theagenio Hospital, Thessaloniki, Greece.

Cancer immunotherapy has been one of the highlights in the advancement of cancer care. Certain immune checkpoint inhibitors bind to PD-1 on T cells and mediate an antitumour immune response. Given that immune checkpoint inhibitors are becoming part of standard care, a new class of adverse events-immune-related adverse events-has emerged. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380640PMC
February 2019
3 Reads

Extended venous thromboembolism prophylaxis after abdominopelvic cancer surgery: a retrospective review.

Curr Oncol 2019 Feb 1;26(1):e106-e110. Epub 2019 Feb 1.

Department of Medicine, McMaster University, Hamilton, ON.

Objective: Extended prophylaxis against venous thromboembolism (vte) after abdominal or pelvic cancer surgery with low molecular weight heparin (lmwh) is recommended by multiple guidelines. The primary objective of the present study was to assess adherence to that guideline recommendation at tertiary care centres within Hamilton Health Sciences (hhs).

Methods: Given that an estimated 70% of the study population would be expected to receive extended prophylaxis, a sample size of 105 patients was calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380653PMC
February 2019
1 Read

Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

Curr Oncol 2019 Feb 1;26(1):e100-e105. Epub 2019 Feb 1.

Department of Medicine, University of Toronto, Toronto, ON.

Background: We examined how conditional market approval of cancer pharmaceuticals by Health Canada (hc) affects public funding recommendations by the pan-Canadian Oncology Review (pcodr). We were also interested to see how often hc conditions are enforced.

Methods: Health Canada and pcodr databases for 2010-2017 were analyzed for patterns in hc conditional authorization and post-authorization reviews of cancer drugs and for correlation with pcodr reimbursement recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380633PMC
February 2019

Patient indications for Mohs micrographic surgery: a clinical practice guideline.

Curr Oncol 2019 Feb 1;26(1):e94-e99. Epub 2019 Feb 1.

Department of Medical Oncology, Odette Cancer Centre, Toronto, ON.

Objective: The purpose of the present work was to develop evidence-based indications for Mohs micrographic surgery in patients with a diagnosis of skin cancer.

Methods: The guideline was developed by Cancer Care Ontario's Program in Evidence-Based Care, together with the Melanoma Disease Site Group and the Surgical Oncology Program, through a systematic review of relevant literature, patient- and caregiver-specific consultation, and internal and external reviews.

Recommendation 1: Given a lack of high-quality, comparative evidence, surgery (with postoperative or intraoperative margin assessment) or radiation (for those who are ineligible for surgery) should remain the standard of care for patients with skin cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380643PMC
February 2019
2 Reads

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Curr Oncol 2019 Feb 1;26(1):e81-e93. Epub 2019 Feb 1.

Ontario: The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa (Laurie); Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa (Brule); University of Toronto, Toronto, and William Osler Health System, Brampton (Cheema); Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto (Cheung); McMaster University, Juravinski Cancer Centre, Hamilton (Juergens); Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto (Leighl); University of Ottawa, The Ottawa Hospital, Ottawa (MacRae); University of Ottawa, Ottawa (Nicholas); R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, and Queen's University, Kingston (Rothenstein); The Ottawa Hospital, The Ottawa Hospital Research Institute, and Division of Medical Oncology, University of Ottawa, Ottawa (Stewart); University Health Network, Princess Margaret Cancer Centre, and University of Toronto, Toronto (Tsao).

Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment.

Methods: An expert panel was convened to define the clinical questions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380642PMC
February 2019

A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.

Curr Oncol 2019 Feb 1;26(1):e70-e80. Epub 2019 Feb 1.

Centre des maladies du sein, Hôpital du Saint-Sacrement, CHU de Québec-Université Laval, Québec, QC.

Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place a significant burden on health care resources and patient quality of life. In an effort to provide a faster and easier administration method, a subcutaneous (sc) formulation of trastuzumab has been developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380645PMC
February 2019

Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases.

Curr Oncol 2019 Feb 1;26(1):e64-e69. Epub 2019 Feb 1.

Centre hospitalier universitaire de Sherbrooke, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC.

Background: Stereotactic radiosurgery (srs) for patients with 5 or more brain metastases (bmets) is a matter of debate. We report our results with that approach and the factors influencing outcome.

Methods: In the 103 patients who underwent srs for the treatment of 5 or more bmets, primary histology was non-small-cell lung cancer (57% of patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380647PMC
February 2019
1 Read

Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

Curr Oncol 2019 Feb 1;26(1):e57-e63. Epub 2019 Feb 1.

Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Fraser Valley Centre, Surrey, and Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC.

Introduction: Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Previous studies have demonstrated a prognostic value for positron emission tomography-computed tomography (pet/ct) parameters, including maximal standardized uptake value (suv), metabolic tumour volume (mtv), and total lesion glycolysis (tlg) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (lc) and overall survival (os) in patients treated with sabr for nsclc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380634PMC
February 2019

Effects of magnanimous therapy on coping, adjustment, and living function in advanced lung cancer.

Authors:
X Huang A Yan Q Liu L Wu

Curr Oncol 2019 Feb 1;26(1):e48-e56. Epub 2019 Feb 1.

The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Hui'ai Hospital), Guangzhou, P.R.C.

Objectives: We examined the effects of magnanimous therapy on psychological coping, adjustment, living function, and survival rate in patients with advanced lung cancer.

Methods: Patients with advanced lung cancer ( = 145) matched by demographics and medical variables were randomly assigned to an individual computer magnanimous therapy group (ic-mt), a group computer magnanimous therapy group (gc-mt), or a control group (ctrl). Over 2 weeks, the ic-mt and gc-mt groups received eight 40-minute sessions of ic-mt or gc-mt respectively, plus usual care; the ctrl group received only usual care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380637PMC
February 2019

Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer.

Curr Oncol 2019 Feb 1;26(1):e39-e47. Epub 2019 Feb 1.

Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, P.R.C.

Background: Combined androgen blockade (cab) is a promising treatment modality for prostate cancer (pca). In the present meta-analysis, we compared the efficacy and safety of first-line cab using an antiandrogen (aa) with castration monotherapy in patients with advanced pca.

Methods: PubMed, embase, Cochrane, and Google Scholar were searched for randomized controlled trials (rcts) published through 12 December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4203DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380654PMC
February 2019
1 Read

Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

Curr Oncol 2019 Feb 1;26(1):e30-e38. Epub 2019 Feb 1.

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education-Beijing), Peking University Cancer Hospital and Institute, Beijing, P.R.C.

Background: The role of systemic inflammation-based markers remains uncertain in advanced or metastatic neuroendocrine tumours (nets).

Methods: Systemic inflammatory factors, such as levels of circulating white blood cells and other blood components, were combined to yield inflammation-based prognostic scores [high-sensitivity inflammation-based Glasgow prognostic score (hsgps), neutrophil:lymphocyte ratio (nlr), platelet:lymphocyte ratio (plr), high-sensitivity inflammation-based prognostic index (hspi), and prognostic nutritional index (pni)], whose individual values as prognostic markers were retrospectively determined. Univariate and multivariate analyses were used to examine the association of inflammatory markers with overall survival (os). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380631PMC
February 2019

Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer.

Curr Oncol 2019 Feb 1;26(1):e24-e29. Epub 2019 Feb 1.

Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Background: Exposing patients with metastatic colorectal cancer (mcrc) to all three active chemotherapeutic agents (oxaliplatin, irinotecan, fluorouracil) has improved survival. The benefit of second-line chemotherapy after a first-line triplet is not clearly defined. We evaluated the efficacy of second-line chemotherapy in patients who had received first-line triplet therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380651PMC
February 2019
1 Read

Selected medical interventions in women with a deleterious mutation: a population-based study in British Columbia.

Curr Oncol 2019 Feb 1;26(1):e17-e23. Epub 2019 Feb 1.

Laboratory Medicine, University of British Columbia, Vancouver, BC.

Background: We examined the uptake of risk-reducing interventions, including bilateral mastectomy, risk-reducing salpingo-oophorectomy, oral contraceptive pills, tamoxifen, and raloxifene, for the entire population of women with a deleterious or mutation in the Canadian province of British Columbia.

Methods: This retrospective population-based study used data available in British Columbia for all women who, between 1996 and 2014, were tested and found to have a mutation. Rates of risk-reducing interventions stratified according to the type of mutation and prior history of breast or gynecologic cancer (ovary, fallopian tube, peritoneal) are presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380629PMC
February 2019
2 Reads

Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study.

Curr Oncol 2019 Feb 1;26(1):e8-e16. Epub 2019 Feb 1.

Evaluative Clinical Sciences, Sunnybrook Research Institute, Toronto, ON.

Purpose: Patient-reported symptom data are collected prospectively by a provincial cancer agency to mitigate the significant symptom burden that patients with cancer experience. However, an assessment of whether such symptom screening occurs uniformly for those patients has yet to be performed. In the present study, we investigated patient, disease, and health system factors associated with receipt of symptom screening in the year after a cancer diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380655PMC
February 2019

Ferocious beast.

Authors:
N A Rutkowski

Curr Oncol 2019 Feb 1;26(1):e6-e7. Epub 2019 Feb 1.

School of Psychology, University of Ottawa, Ottawa, ON.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380638PMC
February 2019

Prevalence of human T cell lymphotropic virus 1 infection in Canada.

Curr Oncol 2019 Feb 1;26(1):e3-e5. Epub 2019 Feb 1.

Division of Dermatology, McGill University, Montreal, QC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380656PMC
February 2019

Secondary polycythemia in a sarcoma patient: a commentary about cediranib.

Authors:
A Awan T Alcindor

Curr Oncol 2019 Feb 1;26(1):e1-e2. Epub 2019 Feb 1.

McGill University Health Centre, Montreal, QC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380644PMC
February 2019
1 Read

Factors influencing the use by radiation therapists of cancer symptom guides: a mixed-methods study.

Curr Oncol 2019 Feb 1;26(1):56-64. Epub 2019 Feb 1.

School of Nursing, University of Ottawa, Ottawa, ON.

Background: Radiation therapists play an important role in helping patients to safely manage and triage potentially life-threatening symptoms. The purpose of the present study was to assess factors influencing the use by radiation therapists of evidence-informed symptom practice guides for patients experiencing cancer treatment-related symptoms.

Methods: In a mixed-methods descriptive study guided by the Knowledge-to-Action framework, interviews and a barriers survey were conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380628PMC
February 2019

Building capacity in cancer knowledge translation through catalyst grants.

Curr Oncol 2019 Feb 1;26(1):55. Epub 2019 Feb 1.

Department of Family and Community Medicine, University of Toronto, and Knowledge Translation Research Network, Health Services Research Network, Ontario Institute for Cancer Research, Toronto, ON.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380646PMC
February 2019

Integrating primary care providers through the seasons of survivorship.

Curr Oncol 2019 Feb 1;26(1):48-54. Epub 2019 Feb 1.

Department of Oncology, Division of Radiation Oncology, Supportive Cancer Care Research Unit, Hamilton, ON.

Traditionally, the role of primary care providers (pcps) across the cancer care trajectory has focused on prevention and early detection. In combination with screening initiatives, new and evolving treatment approaches have contributed to significant improvements in survival in a number of cancer types. For Canadian cancer survivors, the 5-year survival rate is now better than it was a decade ago, and the survivor population is expected to reach 2 million by 2031. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380650PMC
February 2019

Palliative care for cancer patients near end of life in acute-care hospitals across Canada: a look at the inpatient palliative care code.

Curr Oncol 2019 Feb 1;26(1):43-47. Epub 2019 Feb 1.

Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB.

Hospitals play an important role in the care of patients with advanced cancer: nearly half of all cancer deaths occur in acute-care settings. The need for increasing access to palliative care and related support services for patients with cancer in acute-care hospitals is therefore growing. Here, we examine how often and how early in their illness patients with cancer might be receiving palliative care services in the 2 years before their death in an acute-care hospital in Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4563DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380630PMC
February 2019

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.

Curr Oncol 2019 Feb 1;26(1):37-42. Epub 2019 Feb 1.

Royal Victoria Hospital and McGill University, Montreal, QC.

For more than a decade, there has been no improvement in outcomes for patients with unresectable locally advanced (la) non-small-cell lung cancer (nsclc). The standard treatment in that setting is definitive concurrent chemotherapy and radiation (ccrt). Although the intent of treatment is curative, most patients rapidly progress, and their prognosis is poor, with a 5-year overall survival (os) rate in the 15%-25% range. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380636PMC
February 2019

Palliative care consultation and aggressive care at end of life in unresectable pancreatic cancer.

Curr Oncol 2019 Feb 1;26(1):28-36. Epub 2019 Feb 1.

Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS.

Background: Palliative care (pc) consultation has been associated with less aggressive care at end of life in a number of malignancies, but the effect of the consultation timing has not yet been fully characterized. For patients with unresectable pancreatic cancer (upcc), aggressive and resource-intensive treatment at the end of life can be costly, but not necessarily of better quality. In the present study, we investigated the association, if any, between the timing of specialist pc consultation and indicators of aggressive care at end of life in patients with upcc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4389DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380635PMC
February 2019

Adopting patient-centred tools in cancer care: role of evidence and other factors.

Authors:
A Glenn R Urquhart

Curr Oncol 2019 Feb 1;26(1):19-27. Epub 2019 Feb 1.

Queen Elizabeth II Health Sciences Centre, Halifax, NS.

Background: Randomized controlled trials (rcts) provide limited evidence to support the use of survivorship care plans (scps), but they provide strong evidence for patient decision aids (ptdas). Despite that evidence, the uptake of ptdas has been limited, but scps are being endorsed and implemented in many cancer programs across Canada. The objective of the present study was to illuminate the decision-making processes involved in the adoption of scps and ptdas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380639PMC
February 2019

Oncology Association of Naturopathic Physicians: Principles of Care Guidelines.

Curr Oncol 2019 Feb 1;26(1):12-18. Epub 2019 Feb 1.

Hawaii Integrative Oncology, Kailua-Kona, HI, U.S.A.

Patient use of integrative oncology (the inclusion of nonconventional treatments alongside the conventional standard of care) continues to grow, with some studies showing its use in cancer patients to be as high as 91%. Naturopathic physicians are primary care providers who use integrative therapies to deliver patient-centred care. The Oncology Association of Naturopathic Physicians (oncanp) was formed in 2004 as a specialty association for naturopathic physicians providing integrative cancer care (nd oncs). Read More

View Article

Download full-text PDF

Source
http://current-oncology.com/index.php/oncology/article/view/
Publisher Site
http://dx.doi.org/10.3747/co.26.4815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380652PMC
February 2019
4 Reads

Clinical trial implications for study participants accessing medical assistance in dying.

Curr Oncol 2019 Feb 1;26(1):10-11. Epub 2019 Feb 1.

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380649PMC
February 2019

The Oncology Association of Naturopathic Physicians Principles of Care Guidelines.

Authors:
D Seely S Verma

Curr Oncol 2019 Feb 1;26(1):8-9. Epub 2019 Feb 1.

The Ottawa Hospital, and University of Ottawa (retired), Ottawa, ON.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380648PMC
February 2019

Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?

Curr Oncol 2018 12 1;25(6):e610-e614. Epub 2018 Dec 1.

Peter Brojde Lung Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC.

Introduction: Radiotherapy (rt) plays an important role in the treatment of lung cancer. One of the most common comorbidities in patients with lung cancer is pulmonary emphysema. The literature offers conflicting data about whether emphysema increases the occurrence and severity of radiation pneumonitis (rp). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291283PMC
December 2018
3 Reads

Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada.

Curr Oncol 2018 12 1;25(6):e597-e609. Epub 2018 Dec 1.

Colorectal Cancer Canada, Montreal, QC.

Background: Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group.

Methods: A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291290PMC
December 2018
1 Read

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Curr Oncol 2018 12 1;25(6):e592-e596. Epub 2018 Dec 1.

Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC.

Primary effusion lymphoma (pel) is a rare human herpesvirus 8 (hhv8)-related large B cell lymphoma with plasmablastic, immunoblastic, or anaplastic features that often carries a poor prognosis. This lymphoma occurs mainly in patients with hiv infection, most often with Epstein-Barr virus (ebv) co-infection, and usually presents as body cavity effusions or, less commonly, as extracavitary lesions without effusion (ec-pel). Chemotherapeutic treatment options are limited and require concurrent antiretroviral therapy (art). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291272PMC
December 2018
5 Reads

Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Authors:
M Le May S Dent

Curr Oncol 2018 12 1;25(6):e585-e591. Epub 2018 Dec 1.

Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, ON.

Breast cancer is the most common cancer in women, with 15%-25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic syndrome months to years before their cancer diagnosis. Paraneoplastic cerebellar degeneration (pcd) is associated with fewer than 1% of cancers and is strongly associated with breast and gynecologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291278PMC
December 2018
3 Reads

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Curr Oncol 2018 12 1;25(6):e576-e584. Epub 2018 Dec 1.

McGill University Health Centre, Montreal, QC.

Introduction: Outside of randomized controlled clinical trials, the understanding of the effectiveness and costs associated with targeted therapies for metastatic renal cell carcinoma (mrcc) is limited in Canada. The purpose of the present study was to use real-world prospective data to assess the effectiveness and cost of targeted therapies for patients with mrcc.

Methods: The Canadian Kidney Cancer Information System, a pan-Canadian database, was used to identify prospectively collected data relating to patients with mrcc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291289PMC
December 2018
2 Reads

Survival of patients with subglottic squamous cell carcinoma.

Curr Oncol 2018 12 1;25(6):e569-e575. Epub 2018 Dec 1.

Institute for Clinical Evaluative Sciences, Toronto, ON.

Objective: Subglottic squamous cell carcinoma is a rare subsite of laryngeal cancer that behaves more aggressively and portends a worse prognosis. Using a population-based cancer registry, our objective was to report overall survival (os) and laryngectomy-free survival (lfs) in patients diagnosed with subglottic squamous cell carcinoma, and to determine whether primary laryngectomy results in improved survival.

Methods: This retrospective population-based study considered patients with a new diagnosis of squamous cell carcinoma in the province of Ontario over a 15-year period (1995-2009). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3864DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291284PMC
December 2018
9 Reads

Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Curr Oncol 2018 12 1;25(6):e562-e568. Epub 2018 Dec 1.

Division of Surgical Oncology, University of Calgary, Calgary, AB.

Background And Objectives: Contralateral prophylactic mastectomy (cpm) has been increasingly common among women with unilateral invasive breast cancer (ibca) even though the data that support it are limited. Using a population-based cohort, the objectives of the present study were to describe factors predictive of cpm in young women (≤35 years) with ibca and to evaluate the impact of the procedure on mortality.

Methods: All women diagnosed during 1994-2003 and treated with cpm were identified from the Ontario Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291287PMC
December 2018
1 Read

Patient-reported outcome measurement compared with professional judgment of cosmetic results after breast-conserving therapy.

Curr Oncol 2018 12 1;25(6):e553-e561. Epub 2018 Dec 1.

Department of Surgery, Máxima Medical Center, Veldhoven, Netherlands.

Background: In the present study, we set out to compare patient-reported outcomes with professional judgment about cosmesis after breast-conserving therapy (bct) and to evaluate which items (position of the nipple, color, scar, size, shape, and firmness) correlate best with subjective outcome.

Methods: Dutch patients treated with bct between 2008 and 2009 were analyzed. Exclusion criteria were prior amputation or bct of the contralateral breast, metastatic disease, local recurrence, or any prior cosmetic breast surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291275PMC
December 2018
1 Read

Appropriate treatment receipt after breast-conserving surgery.

Curr Oncol 2018 12 1;25(6):e545-e552. Epub 2018 Dec 1.

Schulich School of Medicine and Dentistry, Western University, London.

Background: Breast-conserving surgery (bcs) and radiation therapy (rt) are the standard of care for early breast cancer, although some women receive ipsilateral mastectomy or adjuvant tamoxifen, both of which can be appropriate alternatives to rt. Objectives of the present study were to determine the proportion of women who are treated appropriately after bcs and to identify factors associated with non-receipt of rt.

Methods: This retrospective cohort study used Ontario data linked at the Institute for Clinical and Evaluative Sciences to examine 33,718 patients who received bcs during 2004-2010. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291280PMC
December 2018
1 Read

Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma.

Curr Oncol 2018 12 1;25(6):e539-e544. Epub 2018 Dec 1.

Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB, U.S.A.

Background: Spinal disease (spd) in multiple myeloma (mm) can be a major source of morbidity in newly diagnosed patients and long-term survivors. We retrospectively assessed the incidence of spinal disease in patients newly diagnosed with myeloma, its effect on survival, and the possible effect of spinal radiation therapy (rt).

Methods: Patients diagnosed with mm between 2010 and 2014 were identified through the provincial cancer registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291270PMC
December 2018
9 Reads

Impact of high-fidelity e-learning on knowledge acquisition and satisfaction in radiation oncology trainees.

Curr Oncol 2018 12 1;25(6):e533-e538. Epub 2018 Dec 1.

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON.

Background: e-Learning is an underutilized tool in education for the health professions, and radiation medicine, given its reliance on technology for clinical practice, is well-suited to training simulation in online environments. The purpose of the present study was to evaluate the knowledge impact and user interface satisfaction of high-(hf) compared with low-fidelity (lf) e-learning modules (e-modules) in radiation oncology training.

Methods: Two versions of an e-module on lung radiotherapy (lf and hf) were developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291292PMC
December 2018
1 Read

Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients.

Curr Oncol 2018 12 1;25(6):e527-e532. Epub 2018 Dec 1.

Women's Health Reference Center, Hospital Perola Byington, Sao Paulo, Brazil.

Background: Fertility preservation is an important concern in breast cancer patients. In the present investigation, we set out to create a specific protocol of controlled ovarian stimulation (cos) for oocyte cryopreservation in breast cancer patients.

Methods: From November 2014 to December 2016, 109 patients were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291279PMC
December 2018
2 Reads

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Curr Oncol 2018 12 1;25(6):e516-e526. Epub 2018 Dec 1.

Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON.

Background: Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291274PMC
December 2018
2 Reads

Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial.

Curr Oncol 2018 12 1;25(6):e507-e515. Epub 2018 Dec 1.

Department of Breast Disease, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, P.R.C.

Background: Reducing inflammatory factors in wound exudate is a promising treatment approach for healing wounds in postsurgical breast cancer patients. Traditional Chinese Medicine (tcm) treatments have been shown to be beneficial and safe for optimal regulation of oxidative stress during the postoperative period. In the present clinical trial, we evaluated the effectiveness of a promising Chinese herbal formula, San Huang decoction [shd (Radix astragali, Radix et rhizoma rhei, and Rhizoma curcuma longa, 3:1:1; supplemental Table 1)], on wound inflammatory response after mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291285PMC
December 2018
7 Reads

Adjuvant treatment in older patients with rectal cancer: a population-based review.

Curr Oncol 2018 12 1;25(6):e499-e506. Epub 2018 Dec 1.

Division of Medical Oncology, qeii Health Sciences Centre, Dalhousie University, Halifax, NS.

Background: Little is known about the benefits of adjuvant chemotherapy (adj) in the older population with locally advanced rectal cancer (larc). We evaluated use of adj, survival outcomes, and adj-related toxicity in older patients with larc.

Methods: Our retrospective review included 286 patients with larc (stages ii and iii) diagnosed between January 2010 and December 2013 in Nova Scotia who underwent curative-intent surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291269PMC
December 2018
1 Read

Patients with advanced cancer: when, why, and how to refer to palliative care services.

Curr Oncol 2018 12 1;25(6):403-408. Epub 2018 Dec 1.

Department of Palliative Care, Lachine Hospital Campus of the McGill University Health Centre, Lachine, QC.

Palliative care (pc) is a fundamental component of the cancer care trajectory. Its primary focus is on "the quality of life of people who have a life-threatening illness, and includes pain and symptom management, skilled psychosocial, emotional and spiritual support" to patients and loved ones. Palliative care includes, but is not limited to, end-of-life care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291288PMC
December 2018
1 Read

The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy.

Curr Oncol 2018 12 1;25(6):393-402. Epub 2018 Dec 1.

Department of Surgical Oncology, University Health Network, Toronto, ON.

Purpose: The most prevalent intervention for localized prostate cancer (pca) is radical prostatectomy (rp), which has a 10-year relative survival rate of more than 90%. The improved survival rate has led to a focus on reducing the burden of treatment-related morbidity and improving the patient and partner survivorship experience. Post-rp sexual dysfunction (sdf) has received significant attention, given its substantial effect on patient and partner health-related quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291273PMC
December 2018
1 Read

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Curr Oncol 2018 12 1;25(6):384-392. Epub 2018 Dec 1.

Cross Cancer Institute, Edmonton, AB.

Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer.

Methods: Patients included in the cohort were identified from a registry of patients treated through expanded access to nivolumab before and after Health Canada approval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291291PMC
December 2018
9 Reads

Oncology communities of practice: insights from a qualitative analysis.

Curr Oncol 2018 12 1;25(6):378-383. Epub 2018 Dec 1.

Faculty of Medicine, University of Toronto, Toronto, ON.

Background: A community of practice (cop) is formally defined as a group of people who share a concern or a passion for something they do and who learn how to do it better as they interact regularly. Communities of practice represent a promising approach for improving cancer care outcomes. However, little research is available to guide the development of oncology cops. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291282PMC
December 2018
1 Read

Building an oncology community of practice to improve cancer care.

Curr Oncol 2018 12 1;25(6):371-377. Epub 2018 Dec 1.

Faculty of Medicine, University of Toronto, Toronto, ON.

Background: Communities of practice (cops) have been shown to be effective models for achieving quality outcomes in health care.

Objective: Here, we describe the application of the cop model to the Canadian oncology context.

Methods: We established an oncology cop at our urban community hospital and its networks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291277PMC
December 2018
1 Read

Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer.

Curr Oncol 2018 12 1;25(6):366-370. Epub 2018 Dec 1.

Princess Margaret Cancer Centre, University Health Network, Toronto, ON.

Background: We aimed to assess current treatment patterns and outcomes in elderly patients with localized gastric and esophageal (ge) cancers.

Methods: This retrospective analysis considered patients 75 years of age or older with ge cancers treated during 2012-2014. Patient demographics and tumour characteristics were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291271PMC
December 2018
2 Reads